FDA Guide Clarifies Where To Obtain Cannabis For Clinical Research

FDA on Monday (Jan. 23) published its final guidance on clinical research for cannabis and cannabis-derived compounds, which clarifies where sponsors can obtain cannabis for clinical research purposes and how FDA will consider the abuse potential of investigational cannabis products. The guidance also explains how sponsors can calculate the percentage of delta-9 THC in cannabis product and cites multiple resources, including U.S. Pharmacopeia standards, that product sponsors can use to better understand drug quality and testing expectations. FDA made several...